📋 Tender Overview
Contract awarded for Centralized framework agreement for 24 months for the supply of medicines xiii/2024 { "detected_language": "romanian", "translated_text": "lot-0022, title: combinations type cefalexin atb 250 mg ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0023, title: combinations type chlorzoxazone ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0024, title: combinations type dermovate cream ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0025, title: combinations type codeine phosphate lph 15 mg ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0027, title: combinations type duodart 0.5 mg/0.4 mg or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0034, title: combinations type enalapril 20 mg ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0036, title: combinations type enalapril 10 mg ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0046, title: combinations type arcoxia 90 mg ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0047, title: combinations type arcoxia 120 mg ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0049, title: combinations type fluconazole 100 mg ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0050, title: combinations type fluocinolone ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0055, title: combinations type hydrocortisone acetate ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, estimated value excluding vat: 46602.00 ron.Centralized framework agreement for 24 months for the supply of medicines xiii/2024
